The EIC grant will allow Thirona to accelerate progress in facilitating personalised treatment for lung diseases and drive positive change in patient care.

The funding was awarded following a highly competitive process based on 551 submissions, with Thirona being one of the 51 innovative technology companies selected for the EIC Accelerator grant.

Among the 51 selected companies, 30 per cent have a female CEO or women in executive leadership positions. In addition, 15 of the selected companies have a female CEO, CTO, or CSO.

“We are honoured to be recognised as a trustworthy company with further innovation potential,” says Eva van Rikxoort, CEO and Founder of Thirona.

“The EIC grant will allow us to accelerate personalised treatment for lung diseases, and drive positive change in patient care,” adds Rikxoort.

Founded in 2014 by scientist Eva van Rikxoort, Thirona provides high-precision advanced lung image analysis with AI through expertise-based services for MedTech, pharmaceutical, and CRO companies.

High-precision analyses help develop solutions for screening, diagnostics, and personalised patient treatment.

The Dutch company's AI-based LungQ platform is used to develop solutions that contribute to innovations for screening, diagnostics, and personalised patient treatment of lung diseases. This is done in partnership with pharmaceutical, med-tech, and clinical care integration companies.

Retina division

Earlier this year, the Netherlands' company spun out its Retina division into Thirona Retina BV to concentrate solely on the eye illnesses market.

The company’s flagship AI solution for eye disease screening, RetCAD, uses artificial intelligence to analyse colour fundus images for Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma.

It helps eye care professionals detect and grade disorders that threaten eyesight.